Thanks, Tryz! I am completely psyched abou
Post# of 7769
Posted On: 03/10/2014 8:57:23 AM
Thanks, Tryz!
I am completely psyched about today's fantastic news. The long-awaited RapiMed® initial order from Hong Kong has finally arrived! Link to PR here - http://finance.yahoo.com/news/scripsamerica-s...00942.html. Congratulations to Bob Schneiderman, ScripsAmerica, and all of the patient longs who have endured several months of disappointment and pain. Today, Scrips increased its number of productive revenue streams to five, and this one is big. If anyone has been waiting on the sidelines for a validating sign from the RapiMed® side of the house, look no further than today's announcement. Indeed, I see one big, bright fluorescent sign that reads "ScripsAmerica's RapiMed® - The Real Deal".
As Scrips stated in its Q&A in December: "We firmly believe that our opportunity in China will be a driving catalyst to make 2014 will be a breakout year for ScripsAmerica and our shareholders." And they said it again in today's PR. The $200K order from Hong Kong today begins the breakout. With this initial order, Scrips has spoken loud and clear that it will address the need for more U.S.-made OTC products due to the thousands of deaths caused each year in China as a direct result of ingesting counterfeit OTC products. While the company has not yet entered the Mainland, it will not take long to cross the boarder into Shenzhen and the rest of Mainland China; this would be the sixth productive revenue stream for ScripsAmerica.
Per the Q&A, in 2015, Scrips will be selling Children's RapiMed® into a Chinese pediatric OTC market of approximately $11,000,000,000. And per today's PR, the OTC and pharmaceutical market is about $988,000,000. To illustrate how succeeding in Hong Kong and Mainland China can impact SCRC shareholders, each quarter percent of this $11B market would translate to about $1 in pps ($11B x .0025; $27.5M x .3 (my simple percentage to account for COGS, admin costs, other costs and fees, and taxes) / 135M O/S x 15 PE). Profit margins will be about 50%. This revenue stream is solely capable of delivering the patient shareholders over 800% returns by 2015.
Moreover, considering there are about 30 different possible formulations of the Oral Delivery Technology, Children's RapiMed® in Hong Kong and Mainland China is just the tip of one mammoth iceberg. I also anticipate launching RapiMed® Canada and RapiMed® U.S. in the second half of 2014. How many companies with five to eight productive revenue streams drawing from multibillion dollar global markets are trading on the OTC? In my opinion, the opportunity to a purchase shares of this little gem for a dime or less per share ends this week.
Let's fire up that rocket...March Madness is about to begin!
I am completely psyched about today's fantastic news. The long-awaited RapiMed® initial order from Hong Kong has finally arrived! Link to PR here - http://finance.yahoo.com/news/scripsamerica-s...00942.html. Congratulations to Bob Schneiderman, ScripsAmerica, and all of the patient longs who have endured several months of disappointment and pain. Today, Scrips increased its number of productive revenue streams to five, and this one is big. If anyone has been waiting on the sidelines for a validating sign from the RapiMed® side of the house, look no further than today's announcement. Indeed, I see one big, bright fluorescent sign that reads "ScripsAmerica's RapiMed® - The Real Deal".
As Scrips stated in its Q&A in December: "We firmly believe that our opportunity in China will be a driving catalyst to make 2014 will be a breakout year for ScripsAmerica and our shareholders." And they said it again in today's PR. The $200K order from Hong Kong today begins the breakout. With this initial order, Scrips has spoken loud and clear that it will address the need for more U.S.-made OTC products due to the thousands of deaths caused each year in China as a direct result of ingesting counterfeit OTC products. While the company has not yet entered the Mainland, it will not take long to cross the boarder into Shenzhen and the rest of Mainland China; this would be the sixth productive revenue stream for ScripsAmerica.
Per the Q&A, in 2015, Scrips will be selling Children's RapiMed® into a Chinese pediatric OTC market of approximately $11,000,000,000. And per today's PR, the OTC and pharmaceutical market is about $988,000,000. To illustrate how succeeding in Hong Kong and Mainland China can impact SCRC shareholders, each quarter percent of this $11B market would translate to about $1 in pps ($11B x .0025; $27.5M x .3 (my simple percentage to account for COGS, admin costs, other costs and fees, and taxes) / 135M O/S x 15 PE). Profit margins will be about 50%. This revenue stream is solely capable of delivering the patient shareholders over 800% returns by 2015.
Moreover, considering there are about 30 different possible formulations of the Oral Delivery Technology, Children's RapiMed® in Hong Kong and Mainland China is just the tip of one mammoth iceberg. I also anticipate launching RapiMed® Canada and RapiMed® U.S. in the second half of 2014. How many companies with five to eight productive revenue streams drawing from multibillion dollar global markets are trading on the OTC? In my opinion, the opportunity to a purchase shares of this little gem for a dime or less per share ends this week.
Let's fire up that rocket...March Madness is about to begin!
(0)
(0)